(Q33535030)

English

Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

0 references

1 reference

based on heuristic

inferred from title

imipenem/cilastatin

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dietrich ES

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Patz E

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Frank U

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Daschner FD

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

23-27

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone

1 reference

https://api.crossref.org/works/10.1007%2FBF02565166

21 January 2018

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ceftazidime as first-line therapy for fever in acute leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Clinical Trial Comparing Ceftriaxone/Amikacin versus Ceftazidime/Amikacin as Initial Therapy of Febrile Episodes in Neutropenic Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The costs of treating febrile neutropenia in six U.K. Hospitals

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia

1 reference

https://pubmed.ncbi.nlm.nih.gov/10027102

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF02565166

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33535030&oldid=2195464171"